Alogliptin benzoate is the benzoate salt form of alogliptin which is a selective inhibitor of DPP-4 with IC50 of 6.9 nM that exhibits greater selective than DPP-2, DPP-8 and DPP-9.
Alogliptin Benzoate (SYR-322) is a potent, selective, and orally active DPP-4 inhibitor with an IC50 of less than 10 nM, showing over 10,000-fold selectivity against DPP-8 and DPP-9. It is used in research related to type 2 diabetes[1].[2].[3].
体内研究
Alogliptin (0.01-1 mg/kg; orally) results in dose-dependent improvements in glucose tolerance and elevates plasma insulin levels in female Wistar fatty rats[1].
Alogliptin (40 mg/kg/day for two weeks; orally) decreases infarction size and enhances brain vascular integrity in mice with middle cerebral artery occlusion (MCAO)[3].
体外研究
Alogliptin (1 nM; 5-60 minutes) blocks LPS-induced phosphorylation of ERK in U937 cells[2].
Alogliptin (0.5-5 nM; 24 hours) reduces LPS-induced secretion and mRNA expression of MMP-1, mediated by the ERK pathway, in U937 cells[2].
搜索
